Close Menu

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals announced today that its RNAi-based treatment for Ebola infection, TKM-Ebola-Guinea, has entered Phase II testing in Sierra Leone.

The single-arm, open-label trial is being conducted by the University of Oxford, which is representing the International Severe Acute Respiratory and Emerging Infection Consortium, with funding from the Wellcome Trust.

Data from the study are expected in the second half of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.